These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18794103)

  • 21. High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells.
    Certa U; Seiler M; Padovan E; Spagnoli GC
    Br J Cancer; 2001 Jul; 85(1):107-14. PubMed ID: 11437411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential expression of interferon alpha inducible genes in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus and healthy donors.
    MacParland SA; Corkum CP; Burgess C; Karwowska S; Kroll W; Michalak TI
    Int Immunopharmacol; 2015 Apr; 25(2):545-52. PubMed ID: 25765354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells.
    Henig N; Avidan N; Mandel I; Staun-Ram E; Ginzburg E; Paperna T; Pinter RY; Miller A
    PLoS One; 2013; 8(4):e62366. PubMed ID: 23626809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
    Guillot B; Portalès P; Thanh AD; Merlet S; Dereure O; Clot J; Corbeau P
    Br J Dermatol; 2005 Apr; 152(4):690-6. PubMed ID: 15840100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease.
    Treusch M; Vonthein R; Baur M; Günaydin I; Koch S; Stübiger N; Eckstein AK; Peter HH; Ness T; Zierhut M; Kötter I
    Rheumatology (Oxford); 2004 Oct; 43(10):1275-82. PubMed ID: 15252211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
    Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
    Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder.
    Carballido JA; Moltó LM; Manzano L; Olivier C; Salmerón OJ; Alvarez de Mon M
    Cancer; 1993 Sep; 72(5):1743-8. PubMed ID: 8348503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
    Chevolet I; Schreuer M; Speeckaert R; Neyns B; Hoorens I; van Geel N; Krüse V; Hennart B; Allorge D; Van Gele M; Brochez L
    Melanoma Res; 2015 Aug; 25(4):357-61. PubMed ID: 26050145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
    Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
    Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vivo and vitro effects of interferon-alpha 2b on functional activity of T-lymphocytes from patients with rheumatoid arthritis].
    Iarilina AA; Nikonova MF; Litvina MM; Balabanova RM; Iarilin AA
    Ter Arkh; 2000; 72(5):9-17. PubMed ID: 11109610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Modulation of TLR9 on anti-tumor immune responses of peripheral blood mononuclear cells from patients with non-small-cell lung cancer].
    Ren T; Cai YY; Liang YJ; Jin ML; Guo ZL; Tao MF; He X
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(17):1168-72. PubMed ID: 18844109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56(high+) Interferon-α-induced dendritic cells.
    Nieda M; Terunuma H; Eiraku Y; Deng X; Nicol AJ
    Exp Dermatol; 2015 Jan; 24(1):35-41. PubMed ID: 25363560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegylated interferons Lambda-1a and alfa-2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells.
    Freeman J; Baglino S; Friborg J; Kraft Z; Gray T; Hill M; McPhee F; Hillson J; Lopez-Talavera JC; Wind-Rotolo M
    J Viral Hepat; 2014 Jun; 21(6):e1-9. PubMed ID: 24827902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects.
    Brown L; Roda J; Terrell C; Chaudhury AR; Crespin T; Carson WE; Lesinski GB
    Surgery; 2006 Aug; 140(2):297-306. PubMed ID: 16904983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
    Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
    Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis.
    Korthals M; Safaian N; Kronenwett R; Maihöfer D; Schott M; Papewalis C; Diaz Blanco E; Winter M; Czibere A; Haas R; Kobbe G; Fenk R
    J Transl Med; 2007 Sep; 5():46. PubMed ID: 17894866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-α alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression.
    Konjevic G; Mirjacic-Martinovic K; Vuletic A; Babovic N
    J BUON; 2012; 17(4):761-9. PubMed ID: 23335538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.
    Heise R; Amann PM; Ensslen S; Marquardt Y; Czaja K; Joussen S; Beer D; Abele R; Plewnia G; Tampé R; Merk HF; Hermanns HM; Baron JM
    PLoS One; 2016; 11(1):e0146325. PubMed ID: 26735690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
    Yan W; Wu D; Wang X; Chen T; Lai Q; Zheng Q; Jiang J; Hou J; Han M; Ning Q
    Antivir Ther; 2015; 20(6):591-602. PubMed ID: 25814467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.